ImmunityBio rises after early data for blood cancer cell therapy

** Shares of biotech firm ImmunityBio IBRX.O rise 4.5% to $2.58

** Company says its experimental cell therapy helped disappear all signs of a type of blood cancer in two patients in an early-stage study

** The therapy, CD19 CAR-NK, is being developed to treat Waldenstrom macroglobulinemia — a rare, slow-growing cancer that affects white blood cells

** The therapy was well tolerated by the patients with no significant toxic side effects - IBRX

** One of the patients who received CD19 CAR-NK in combination with an antibody drug rituximab remains in remission after six months of treatment - IBRX

** Including session moves, shares up 2.5% YTD